ProQR Therapeutics NV (NASDAQ:PRQR) gapped up before the market opened on Monday . The stock had previously closed at $5.18, but opened at $5.20. ProQR Therapeutics NV shares last traded at $5.25, with a volume of 10,966 shares.

A number of equities research analysts have recently issued reports on PRQR shares. Leerink Swann reiterated a “buy” rating on shares of ProQR Therapeutics NV in a research note on Thursday. Zacks Investment Research cut ProQR Therapeutics NV from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Chardan Capital started coverage on ProQR Therapeutics NV in a research note on Monday, June 20th. They set a “neutral” rating and a $4.50 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $15.94.

The firm’s market cap is $127.00 million. The firm has a 50-day moving average price of $4.98 and a 200-day moving average price of $4.89.

ProQR Therapeutics NV (NASDAQ:PRQR) last announced its quarterly earnings data on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.48) by $0.00. On average, equities research analysts anticipate that ProQR Therapeutics NV will post ($1.80) earnings per share for the current fiscal year.

An institutional investor recently raised its position in ProQR Therapeutics NV stock. Jennison Associates LLC boosted its position in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 3.4% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,001,774 shares of the biopharmaceutical company’s stock after buying an additional 33,019 shares during the period. Jennison Associates LLC owned 4.29% of ProQR Therapeutics NV worth $8,695,000 as of its most recent SEC filing.

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.